Polypharmacy in Parkinson’s disease: risks and benefits with little evidence

‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease

C. Savio Chan, Jaime N. Guzmán, Ema Ilijić et al. · Nature · 2007 · 906 citations

Life Sciences, Neurobiology, Neuroscience +16

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Dilan Athauda, Kate Maclagan, Simon S. Skene et al. · The Lancet · 2017 · 851 citations · Full text

Medicine, Neurology, Pharmacology +12

Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B₁₂Deficiency

Jameson R. Lam, Jennifer L. Schneider, Wei Zhao et al. · JAMA · 2013 · 577 citations

Medicine, Pharmacology, Pharmacotherapy +12

A controlled trial of antidepressants in patients with Parkinson disease and depression

Matthew Menza, Roseanne D. Dobkin, Humberto Marín et al. · Neurology · 2008 · 408 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

Mark H. Corrigan, Angelita Q. Denahan, Caroline Wright et al. · Depression and Anxiety · 2000 · 361 citations

Pharmacy, Pharmacotherapy, Psychiatry +17